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Photodynamic therapy (PDT) is an approved clinical technique 
for the treatment of malignancies. PDT involves the topical or
systemic application of a photosensitizing agent followed by illu-
mination at a specific ‘activating’ wavelength of light (Gomer et
al, 1988; Jamieson et al, 1993; Kick et al, 1995). Light activation
of photosensitizers is believed to kill cells by catalysing the
production of reactive oxygen intermediates (Gomer et al, 1988).
Our laboratory is interested in the biological activity of the
chlorin-type photosensitizer, benzoporphyrin derivative monoacid
ring A (BPD-MA) (Richter et al, 1987). BPD-MA accumulates to
higher levels in leukaemic cells compared with normal blood
mononuclear cells (Jamieson et al, 1990, 1993). Further, using
light-activated BPD-MA, in vitro experiments have demonstrated
a selective killing of leukaemic cells over normal haematopoietic
progenitor cells (Jamieson et al, 1990; Gluck et al, 1996). Electron
microscopy, histological and biochemical studies have shown that
PDT with a variety of photosensitizers induces apoptosis in
different cell types (Gomer et al, 1988; Zaidi et al, 1993; Tajiri 
et al, 1996; Granville et al, 1997). Treatment of human promyelo-
cytic leukaemia HL-60 cells with BPD-MA and light rapidly
induces DNA fragmentation, caspase activation and apoptotic cell
death (Granville et al, 1997, 1998a). However, it cannot be ruled
out that PDT might also inflict damage to cells which promote
passive necrotic cell death (Noodt et al, 1996).
It is now established that proteolytic cleavage of key cellular
substrates is a fundamental biochemical event underlying the
apoptotic process (Casciola-Rosen et al, 1996). One of the most
intensively studied of these proteases, caspase 3 (previously
termed CPP32/Yama/apopain), normally resides in the cytosolic
fraction of cells as an inactive precursor and is proteolytically
activated in cells undergoing apoptosis (Schlegel et al, 1996).
Increasing numbers of caspase 3 substrates have been identified
and include poly(ADP-ribose) polymerase (PARP) (Nicholson et
al, 1995), sterol regulatory element binding proteins (Wang et al,
1996), the U1-associated 70-kDa protein (Casciola-Rosen et al,
1996), DNA-dependent protein kinase (Casciola-Rosen et al,
1996) and DNA fragmentation factor (DFF) (Liu et al, 1997).
Recent studies have demonstrated that caspase 3 activation and
DNA fragmentation are directly linked through the caspase-3-
mediated cleavage of DNA fragmentation factor (DFF) (also
known as inhibitor of caspase-activated deoxyribonuclease,
ICAD), a cytosolic factor which binds to and inhibits the 
activity of an endonuclease (caspase-activated nuclease, CPAN 
or caspase-activated deoxyribonuclease, CAD) directly respon-
sible for DNA fragmentation during apoptosis (Liu et al, 1997;
Enari et al, 1998; Halenbeck et al, 1998, Sakahira et al, 1998). This
endonuclease, CAD/CPAN, is only activated during apoptosis 
and is, therefore, believed to be responsible for DNA frag-
mentation (Halenbeck et al, 1998; Sakahira et al, 1998). We have
shown that caspase-3-dependent cleavage of DFF occurs in PDT-
treated HL-60 (Granville et al, 1998b) and HeLa cells (Carthy et
al, 1998).
Caspase 6 (Mch2) is also mobilized in response to certain apo-
ptotic stimuli (Fernandes-Alnemri et al, 1995; Orth et al, 1996;
Srinivasula et al, 1996). Caspase 6 is believed to be responsible 
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Summary Treatment with the photosensitizer benzoporphyrin derivative monoacid ring A (BPD-MA, verteporfin) followed by irradiation with
visible light induces apoptosis in human acute myelogenous leukaemia HL-60 cells. Photoactivation of BPD-MA induces procaspase 3
(CPP32/Yama/apopain) and procaspase 6 (Mch2) cleavage into their proteolytically active subunits in these cells. The Bcl-2 proto-oncogene
product has been shown to protect cells from a number of proapoptotic stimuli. In the present study, the influence of Bcl-2 overexpression on
cellular resistance to photoactivation of BPD-MA was studied. Overexpression of Bcl-2 in HL-60 cells prevented apoptosis-related events
including caspase 3 and 6 activation, poly(ADP-ribose) polymerase cleavage and the formation of hypodiploid DNA produced by BPD-MA
(0–200 ng ml–1) and light. However, Bcl-2 overexpression was less effective at preventing cell death that occurred after photoactivation at high
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Avenue, Vancouver, BC V5Z 4H5, Canadafor nuclear lamin cleavage which may contribute to the nuclear
degradation observed during apoptosis (Orth et al, 1996;
Srinivasula et al, 1996; Takahashi et al, 1996).
One of the most studied cell survival genes is Bcl-2 (Gajewski
and Thompson, 1996; Reed, 1997). Bcl-2 was discovered as an
overexpressed protein in human B-cell lymphomas arising as a
result of a t(14;18) chromosomal translocation (Pegoraro et al,
1984; Tsujimoto et al, 1985). The overexpression of Bcl-2 has
been shown to protect different cell types against apoptosis
induced by such diverse stimuli as viral infection, hypoxia,
ionizing radiation or chemotherapeutic agents (Shimizu et al,
1995; Gajewski and Thompson, 1996; Ibrado et al, 1996, 1997;
Reed, 1996). Bcl-2 overexpression in Chinese hamster ovary cells
provided partial protection against the loss of clonogenicity
produced by PDT using phthalocyanine Pc4 (He et al, 1996),
supporting a role for Bcl-2 in the regulation of PDT-induced apop-
tosis. Several members of the Bcl-2 family have been identified in
mammals: Bcl-2, Bcl-XL, A1/Bfl-1, Bcl-w, Nr13 and Mcl-1 serve
to inhibit apoptosis, whereas Bax, Bik, Bak, Bad and Bcl-XS
promote apoptosis (Reed, 1996; Nagata, 1997). Members of 
the Bcl-2 family have been shown to homo- or heterodimerize
with one another to either antagonize or enhance the function of
the other (Yang et al, 1995; Reed, 1996). In vivo and in vitro
studies showed that Bcl-2 provides protection against apoptosis 
in the absence of protein translation, suggesting that it does not
exert its protective effect through gene regulation (Rowan and
Fisher, 1997). Bcl-2 is an integral membrane protein that is situ-
ated primarily on the outer membranes of mitochondria, endo-
plasmic reticulum and nuclei (Nagata, 1997; Yang et al, 1997). In
some systems, Bcl-2 regulates intracellular Ca2+ levels and
prevents the loss of mitochondrial membrane potential produced
by proapoptotic stimuli (Rowan and Fisher, 1997). Recent
evidence suggests that Bcl-2 may act as an ion channel and regu-
late the release of cytochrome c from the mitochondria, an event
that may be necessary for caspase 3 activation (Kluck et al, 1997;
Yang et al, 1997).
We have previously demonstrated that caspase 3, but not
caspase 1, is activated leading to PARP and DNA-PK cleavage in
HL-60 cells treated with cytotoxic levels of BPD-MA and light
(Granville et al, 1997). The present report shows that although
Bcl-2 overexpression effectively blocked caspase 3 and caspase 6
activation as well as hypodiploid DNA formation produced by
PDT, Bcl-2 had little or no effect on cell death induced by the
photoactivation of BPD-MA at high drug doses but did offer a
degree of protection against killing at lower levels of the photo-
sensitizer as determined by 3-day culture studies.
MATERIALS AND METHODS
Reagents and cell culture
Liposomally formulated BPD-MA was from QLT Photo-
Therapeutics (Vancouver, BC, Canada). All antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). All other drugs and chemicals, unless specified, were
obtained from Sigma Chemical (St. Louis, MO, USA). The
transfected human promyelocytic leukaemia HL-60/neo and HL-
60/Bcl-2 cell lines were generously provided by Dr Kapil Bhalla
(Emory University School of Medicine, Atlanta, GA, USA).
Detailed methods used to generate these clones have been previ-
ously described (Ibrado et al, 1996). The HL-60/Bcl-2 cells used
in this study contain a fivefold higher level of Bcl-2 than the HL-
60/neo control cells, whereas Bcl-XL and Bax levels are com-
parable for both transfectants (Ibrado et al, 1996). Cells were
maintained in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 4 mML -glutamine, 1 mM
sodium pyruvate, 1 mM Hepes, penicillin (100 U ml–1) and strepto-
mycin (100 mg ml–1) (Gibco, Burlington, Ontario, Canada) and
G418 (1 mg ml–1) (Geneticin; Life Technologies, Grand Island,
NY, USA).
PDT and inhibitor treatment of cells
For photodynamic studies, cells were incubated for a total of 60
min at 37°C with BPD-MA (0–200 ng ml–1) in RPMI containing
10% FBS. After incubation with BPD-MA, cells were exposed to
fluorescent red light (620–700 nm) delivered at 5.6 mW cm–2 to
give a total dose of 2 J cm–2. For caspase 3 inhibition studies, Z-
DEVD-fmk (Enzyme Systems Products, Dublin, CA, USA) was
added to the cells to give final concentrations of 10, 20 or 25 mM
for the final 30 min before photoactivation.
Analysis of DNA status
The propidium iodide (PI) fluorescence analysis procedure 
was used to detect changes in the status of cellular DNA
(Darzynkieicz et al, 1992; Telford et al, 1994). At 3 h, after PDT, 
1 ´ 106 cells were washed twice with ice-cold PBS then per-
meabilized and fixed in 80% ethanol at 4°C for 1 h. Cells were
washed twice in ice-cold PBS and treated with RNAase (5 U ml–1,
DNAase-free) and stained with PI (50 mg ml–1) in PBS. Samples
were analysed by flow cytometry. The percentage of cells
containing hypodiploid levels of DNA was calculated from single
parameter flow cytometry for PI fluorescence (Telford et al, 1994)
using an Epics XL flow cytometer (Coulter Electronics, Hialeah,
FA, USA).
Preparation of cellular protein extracts
To prepare cell lysates, cells were initially washed twice with ice-
cold PBS. Cell pellets were treated with 1 ml of lysis buffer [1%
Nonidet P-40 detergent (NP-40), 20 mM Tris, pH 8, 137 mM
sodium chloride, 10% glycerol] supplemented with 1 mM phenyl-
methylsulphonyl fluoride (PMSF), aprotinin (0.15 U ml–1) and 
1m M sodium orthovanadate for 20 min on ice. Lysates were
centrifuged for 10 min at 15 800 g at 4°C. Protein concentrations
of cell extracts were determined with the Pierce BCA protein
assay (Pierce, Rockford, IL, USA).
Protease assay
To evaluate caspase 3 activity, cell lysates were prepared 1 h after
their respective treatment. Assays were performed in 96-
well microtitre plates by incubating 25 ml (10 mg protein) of cell
lysate in 125 ml of reaction buffer (1% NP-40, 20 mM tris-HCl, pH
7.5, 137 mM sodium chloride, 10% glycerol) containing the
caspase-3 substrate [Acetyl-Asp-Glu-Val-Asp-amino-4-methyl-
coumarin (Ac-DEVD-AMC)] (Calbiochem, Cambridge, MA,
USA) at 100 mM. Lysates were incubated at 37°C for 16 h and
fluorescence levels were determined using a CytoFluor 2350
(PerSeptive Biosystems, Burlington, ON, USA) set at excitation
and emission wavelengths of 380 nm and 460 nm respectively.
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Detergent-soluble proteins (30 mg) were separated by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
in 12% gels, under reducing conditions (Laemmli, 1970). Proteins
were transferred to nitrocellulose membranes at 100 V for 1 h.
Membranes were blocked for 30 min at room temperature with 5%
skimmed milk powder in PBS-0.05% Tween 20 (PBS-T). Mem-
branes were incubated for 45 min using the following polyclonal
antibodies: goat-anti-PARP, goat-anti-CPP32, goat-anti-Mch2 or
rabbit-anti-Bcl-2 at 1 mg ml–1. Membranes were then probed with
anti-goat IgG-HRP or anti-rabbit IgG-HRP (1:5000) in PBS-T with
1% skimmed milk powder for 30 min at room temperature.
Membranes were rinsed twice in PBS-T, followed by three 15-min
washes with PBS-T. Proteins were detected using the enhanced
chemiluminescence detection system (Amersham, Arlington
Heights, IL, USA) and bands visualized by autoradiography.
Assessment of cell viability using MTT
To assess cell viability, 5 ´ 104 cells were loaded into eight repli-
cate wells (0.2 ml per well) of 96-well microtitre plates. After 3,
24, 48 or 72 h, 10 ml of a MTT solution (5 mg ml–1) was added to
each well (Mosmann, 1983). Cells were incubated for a further 1 h
at 37°C. The reaction was stopped by the addition of 150 ml of
acidified isopropanol. The degree of colour development was
analysed with an automated densitometer microtitre plate reader
(Dynatech, Hamilton, VA, USA) using a 590-nm filter.
RESULTS
Caspase 6 activation occurs downstream of caspase 3
To assess the involvement of caspases in PDT-induced apoptosis,
wild-type HL-60 cells were treated with different amounts of the
caspase 3 inhibitor Z-DEVD-fmk before BPD-MA photoactiva-
tion. The presence of Z-DEVD-fmk did not affect PDT-induced
caspase-3 cleavage and the appearance of the 12-kDa cleavage
product at the concentrations tested (Figure 1). However, when the
membrane was probed with either anti-caspase 6 or anti-PARP
antibodies, it was evident that PDT-induced cleavage of these
proteins was greatly reduced at a 25 mM concentration of Z-
DEVD-fmk. The PDT-induced increase in hypodiploid DNA was
also blocked at this concentration of the tetrapeptide inhibitor. A
lower concentration of Z-DEVD-fmk (10 mM) did not block the
cleavage of procaspase 6 or PARP, nor affect the appearance of
hypodiploid levels of DNA (Figure 1). These results demonstrate
that caspase 6 is activated by PDT and may occur downstream of
caspase-3 processing.
Overexpression of Bcl-2 blocks caspase 3 and 
caspase 6 cleavage
To assess the influence of Bcl-2 overexpression and susceptibility
to photodynamic killing, HL-60/neo or HL-60/Bcl-2 cells were
incubated with or without BPD-MA and then exposed to light.
Cells were lysed 1 h after light activation of BPD-MA. The status
of Bcl-2, caspase 3 and caspase 6 in cytosolic extracts was
Bcl-2 alters PDT-induced cell death 97
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Figure 1 Caspase 3 activation precedes procaspase 6 and PARP cleavage
induced by treatment with BPD-MA (100 ng ml–1) and light (PDT-100). HL-60
cells were treated with a caspase 3 inhibitor (Z-DEVD-fmk) before
photoactivation of BPD-MA. (A) Cell lysates, prepared 1 h post-PDT, were
separated by SDS-PAGE and analysed by Western blotting to determine the
status of caspase 3, caspase 6 and PARP. (B) Relative levels of hypodiploid
DNA in cells produced by the different treatment regimens at 3 h post-PDT.
Cells were treated with light alone (2 J cm–2) (control), BPD-MA alone 
(100 ng ml–1), BPD-MA (100 ng ml–1) and light (PDT-100), or PDT-100 and Z-
DEVD-AMC at the indicated concentrations
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Figure 2 Overexpression of Bcl-2 in HL-60 cells blocks the processing of
procaspase 3 and procaspase 6 induced by treatment with BPD-MA and
light. Cells were lysed 1 h after photosensitization. Cell lysates were
separated by SDS-PAGE followed by Western immunoblotting. Cells were
treated with light alone (2 J cm–2) (control), BPD-MA alone (100 ng ml–1) and
light (PDT-100), or BPD-MA (200 ng ml–1 and light (PDT-200)determined by Western immunoblotting. The control Bcl-2-trans-
fected cells exhibited the expected greater band density of Bcl-2
(Figure 2). The electrophoretic status of Bcl-2 was unaffected by
PDT treatment of either cell type (HL-60/neo or HL-60/Bcl-2).
For cells treated with BPD-MA and light, caspase 3 and caspase 6
cleavage was evident for HL-60/neo cell lysates, but not in the HL-
60/Bcl-2 cell extracts (Figure 2). These results suggest that Bcl-2
may indirectly or directly influence caspase 3 and caspase 6 acti-
vation produced by PDT.
Overexpression of Bcl-2 blocks caspase 3-like 
protease activity
Cell lysates were assayed for their capacity to cleave a fluorescently
labelled caspase 3 substrate (Ac-DEVD-AMC) (Figure 3). Lysates
prepared from HL-60/neo cells treated with BPD-MA and light
exhibited high Ac-DEVD-AMC cleavage activity, whereas lysates
from HL-60/Bcl-2 cells treated with the same levels of BPD-MA and
light exhibited baseline levels of substrate cleavage. These results
further support the observation that overexpression of Bcl-2 blocks
activation of caspase 3 instigated by BPD-MA photoactivation.
Overexpression of Bcl-2 blocks PDT-induced 
increases in hypodiploid DNA
HL-60/neo and HL-60/Bcl-2 cells were analysed for their 
DNA status 3 or 24 h after BPD-MA photoactivation (Figure 4).
HL-60/neo cells treated with BPD-MA and light exhibited high
levels of hypodiploid DNA, suggestive of DNA fragmentation,
compared with untreated cells and cells treated with light or BPD-
MA alone. However, there was no evidence of PDT-induced DNA
fragmentation (cells < 2n DNA) for HL-60/Bcl-2 cells treated with
BPD-MA and light at 3 h after photoactivation and only a slight
increase in hypodiploid DNA by 24 h. These results indicate that
overexpression of Bcl-2 in HL-60 cells prevents the appearance of
hypodiploid DNA induced by BPD-MA and light.
Overexpression of Bcl-2 provides partial protection
against cell death at low levels of PDT
Our final step was to examine the effect of Bcl-2 overexpression on
the viability of cells treated with BPD-MA and light. HL-60/neo
and HL-60/Bcl-2 cells were incubated with titrated amounts of
BPD-MA and exposed to light 1 h later. Bioreduction of MTT was
used to compare the viability of each cell type at  3, 24, 48 and 72 h
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Figure 4 Overexpression of Bcl-2 in HL-60 cells blocks PDT-induced
hypodiploid DNA formation. HL-60/neo (n n) and HL-60/Bcl-2 (n) cells were
assessed for the presence of hypodiploid DNA by PI staining, (A) 3 h or (B)
24 h after the indicated treatments. Cells were treated with medium (control),
BPD-MA (100 ng ml–1), BPD-MA (100 ng ml–1) and light (2 J cm–2) (PDT-100),
or BPD-MA (200 ng ml–1) and light (2 J cm–2) (PDT-200). Mean values with
s.d. for three independent experiments are shown
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Figure 3 Overexpression of Bcl-2 blocks the induction of DEVD-ase activity
associated with PDT. AT 1 h after treatment, HL-60/neo (n) or HL-60/Bcl-2
(n n) cell lysates were prepared and assayed for their capacity to cleave a
fluorescently labelled caspase 3 substrate (Ac-DEVD-AMC). Cytosolic
extracts were taken from untreated cells (control) or cells treated with BPD-
MA (100 ng ml–1) alone, BPD-MA (100 ng ml–1) and light (2 J cm–2) (PDT-100)
or BPD-MA (200 ng ml–1) and light (2 J cm–2) (PDT-200). Error bars represent
standard deviations (s.d.) of the mean values obtained in three experiments
using replicates of five for each treatment sample
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Figure 5 Overexpression of Bcl-2 provides protection against PDT-induced
cell death only for cells treated with concentrations of BPD-MA of 25 ng ml–1
or less. HL-60/neo (l l) and HL-60/Bcl-2 (l) cells were incubated with BPD-
MA (0–100 ng ml–1) and exposed to light 1 h later. Cell viability was assayed
3, 24, 48 or 72 h later by measuring the bioreduction of MTT. Data are
expressed as a percentage of the result obtained with untreated control cells.
Error bars represent the s.d. of mean values from two experiments using
eight replicates for each treatmentafter PDT. Overexpression of Bcl-2 provided  no observable protec-
tion at concentrations of BPD-MA at 50 or 100 ng ml–1, as
measured by MTT bioreduction over a 72-h period (Figure 5).
However, at lower concentrations of BPD-MA (10 or 25 ng ml–1),
Bcl-2 overexpression did provide a degree of protection against
photodynamic inactivation of a small proportion  of cells which
exhibited recovery over the 72-h test period.
DISCUSSION
Overexpression of Bcl-2 has been shown to protect many different
cancer cell lines from apoptosis induced by a wide variety of
chemotherapeutic agents including dexamethasone, etoposide,
methotrexate, cisplatin, cyclophosphamide, vincristine and 1-beta-
D-arabinofuranosylcytosine (Ara-C) (reviewed in Reed, 1996). It
has been observed that Bcl-2 overexpression blocks caspase 3 acti-
vation and subsequent PARP cleavage in these systems (Ibrado et
al, 1996; Estoppey et al, 1997; Perry et al, 1997). In this study, we
evaluated caspase activity, DNA fragmentation (as evidenced by
an increase in hypodiploid DNA) and the viability of HL-60/neo or
HL-60/Bcl-2 cells to determine whether treatment with cytotoxic
levels of BPD-MA and light was regulated in a similar fashion in
the setting of Bcl-2 overexpression.
Overexpression of Bcl-2 prevented procaspase 3 and PARP
cleavage produced by PDT. Such findings correspond to previous
results obtained with these cells in which Ara-C was used as the
apoptotic stimulus (Ibrado et al, 1996). Procaspase 6 was also not
processed in HL-60/Bcl-2 cells, indicating that Bcl-2 also acts
upstream of caspase 6 activation in cells treated with BPD-MA
and light. It has been demonstrated that caspase 6 may be respon-
sible for degradation of nuclear lamins during apoptosis (Lazebnik
et al, 1995; Neamati et al, 1995; Takahashi et al, 1996). Lamin
cleavage may be critical for the degradation of the nuclear enve-
lope during apoptotic cell death (Lazebnik et al, 1995). Studies by
others have shown that caspase 3 can directly cleave procaspase 6
(Srinivasula et al, 1996), suggesting that procaspase 6 cleavage
does not occur in PDT-treated HL-60/Bcl-2 cells because of the
absence of caspase 3 activity. Conversely, a recent report by
Thornberry et al (1997) suggests that the optimal amino acid
substrate sequence for caspase 6 resembles the activation site in
effector caspase proenzymes such as caspase 3, suggesting that
caspase 6 may act upstream of caspase 3 (Thornberry et al, 1997).
To determine whether caspase 6 activation occurred downstream
of caspase 3, wild-type HL-60 cells were incubated with a caspase
3 inhibitor, Z-DEVD-fmk, before photoactivation of BPD-MA.
The caspase 3 inhibitor did not block the appearance of the 12-kDa
subunit of caspase 3, as produced by PDT, but did prevent the
cleavage of procaspase 6 and PARP indicating that procaspase 6
cleavage is probably downstream of caspase 3 activation.
Cytosolic extracts prepared from HL-60/Bcl-2 cells exhibited
minimal cleavage of the Ac-DEVD-AMC substrate in contrast to
the HL-60/neo cells treated with the same amounts of BPD-MA
and light. Interestingly, untreated HL-60/Bcl-2 cells, or those
exposed to the photosensitizer in the absence of light, had a lower
constitutive capacity to cleave the Ac-DEVD-AMC substrate than
the HL-60/neo cells. This observation could be attributable to the
presence of a minor proportion of apoptotic cells within the HL-
60/neo cell population exhibiting caspase activity. Background
levels of protease activity would be less for HL-60/Bcl-2 cells
because overexpression of Bcl-2 inhibits caspase 3 activation
(Ibrado et al, 1996).
Several studies have now demonstrated that cytochrome c may
be necessary for the activation of caspase 3 and that Bcl-2 blocks
the release of cytochrome c from mitochondria (Kluck et al, 1997;
Yang et al, 1997). Furthermore, it has recently been demonstrated
that cytochrome c is involved in the activation of caspase 9, which
is believed to then process caspase 3 (Li et al, 1997). Whether this
scenario transpires in PDT-treated cells will be examined in future
studies.
For HL-60/Bcl-2 cells treated with BPD-MA and light, cell
survival was not detected at photosensitizer concentrations of 50 ng
ml–1 or greater at 72 h post PDT, suggesting that PDT may circum-
vent the inhibitory function of Bcl-2. The photodynamic treatment
did not override the inhibitory effects of Bcl-2 with respect to
caspase 3 and caspase 6 activation because procaspase  3 and 6
cleavage or DNA fragmentation did not occur in the  HL-60/Bcl-2
cells that were treated with BPD-MA (100 ng ml–1) and light. This
would suggest that a parallel biochemical pathway unrelated to
caspases may be triggered in cells treated with higher levels of BPD-
MA and light. At BPD-MA concentrations of less than 50 ng ml–1, a
modest protective effect of Bcl-2 overexpression against PDT-medi-
ated cell death was observed in line with observations for other
chemotherapeutic treatments (Reed et al, 1996). Although it has
been well established by electron microscopy, histological and
biochemical analysis that PDT induces apoptosis, we cannot rule out
the possibility that PDT inflicts damage to other cell sites promoting
passive necrotic cell death at higher drug concentrations (Gomer et
al, 1988; Zaidi et al, 1993; Tajiri et al, 1996; Granville et al, 1997).
Further understanding towards the mechanisms involved in PDT-
induced cell death and how this treatment may be able to overcome
the regulatory control of Bcl-2 should provide valuable insights
towards the improvement of current cancer treatments.
ABBREVIATIONS
Ac-DEVD-AMC, acetyl-Asp-Glu-Val-Asp-amino-4-methyl-
coumarin; BPD-MA, benzoporphyrin monoacid ring A,
verteporfin, ICE, interleukin 1 converting enzyme; MTT, 3-(4,4-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; PARP,
poly(ADP-ribose) polymerase; PDT, photodynamic therapy; PI,
propidium iodide; Z-DEVD-fmk, Z-Asp-Glu-Val-Asp-fluoro-
methylketone.
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